The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Bad Bugs Need Drugs: An Update on the Development Pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America
Abstract
The Antimicrobial Availability Task Force (AATF) of the Infectious Diseases Society of America (IDSA) has viewed with concern the decreasing investment by major pharmaceutical companies in antimicrobial research and development. Although smaller companies are stepping forward to address this gap, their success is uncertain. The IDSA proposed legislative and other federal solutions to this emerging public health problem in its July 2004 policy report "Bad Bugs, No Drugs: As Antibiotic R&D Stagnates, a Public Health Crisis Brews." At this time, the legislative response cannot be predicted. To emphasize further the urgency of the problem for the benefit of legislators and policy makers and to capture the ongoing frustration our clinician colleagues experience in their frequent return to an inadequate medicine cabinet, the AATF has prepared this review to highlight pathogens that are frequently resistant to licensed antimicrobials and for which few, if any, potentially effective drugs are identifiable in the late-stage development pipeline.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496
System, A. R. F. T. N. (2003) · American Journal of Infection Control · doi:10.1016/j.ajic.2003.09.002 · Cited by 2,915
System, A. R. F. T. N. (2004) · American Journal of Infection Control · doi:10.1016/j.ajic.2004.10.001 · Cited by 2,342
Cosgrove, S. E., Sakoulas, G., Perencevich, E. N., Schwaber, M. J., Karchmer, A. W., & Carmeli, Y. (2003) · Clinical Infectious Diseases · doi:10.1086/345476 · Cited by 1,964
Falagas, M. E., Kasiakou, S. K., & Saravolatz, L. D. (2005) · Clinical Infectious Diseases · doi:10.1086/429323 · Cited by 1,744
Vandenesch, F., Naimi, T., Enright, M. C., Lina, G., Nimmo, G. R., Heffernan, H., Liassine, N., Bes, M., Greenland, T., Reverdy, M.-E., et al. (2003) · Emerging Infectious Diseases · doi:10.3201/eid0908.030089 · Cited by 1,727
Denning, D. W. (1998) · Clinical Infectious Diseases · doi:10.1086/513943 · Cited by 1,492
Multiple Mechanisms of Antimicrobial Resistance in Pseudomonas aeruginosa: Our Worst Nightmare?
Livermore, D. M. (2002) · Clinical Infectious Diseases · doi:10.1086/338782 · Cited by 1,453
Metallo-β-Lactamases: the Quiet before the Storm?
Walsh, T. R., Toleman, M. A., Poirel, L., & Nordmann, P. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.2.306-325.2005 · Cited by 1,431
Overview of Nosocomial Infections Caused by Gram-Negative Bacilli
Weinstein, R. A., Gaynes, R., Edwards, J. R., & System, N. N. I. S. (2005) · Clinical Infectious Diseases · doi:10.1086/432803 · Cited by 1,404
Self-citationLiposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and Neutropenia
Walsh, T. J., Finberg, R. W., Arndt, C., Hiemenz, J., Schwartz, C., Bodensteiner, D., Pappas, P., Seibel, N., Greenberg, R. N., Dummer, S., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401004 · Cited by 1,205
Walsh, T. J., Pappas, P., Winston, D. J., Lazarus, H. M., Petersen, F., Raffalli, J., Yanovich, S., Stiff, P., Greenberg, R., Donowitz, G., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejm200201243460403 · Cited by 979
Engemann, J. J., Carmeli, Y., Cosgrove, S. E., Fowler, V. G., Bronstein, M. Z., Trivette, S. L., Briggs, J. P., Sexton, D. J., & Kaye, K. S. (2003) · Clinical Infectious Diseases · doi:10.1086/367653 · Cited by 934
Walsh, T. J., Teppler, H., Donowitz, G. R., Maertens, J. A., Baden, L. R., Dmoszynska, A., Cornely, O. A., Bourque, M. R., Lupinacci, R. J., Sable, C. A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040446 · Cited by 919
Vancomycin-Resistant Enterococcal Infections
Murray, B. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003093421007 · Cited by 890
Trends in antimicrobial drug development: Implications for the future
Spellberg, B., Powers, J. H., Brass, E. P., Miller, L. G., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/420937 · Cited by 867
Self-citationJacoby, G. A., & Munoz-Price, L. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041359 · Cited by 787
Paterson, D. L., Ko, W.-C., Gottberg, A. V., Mohapatra, S., Casellas, J. M., Goossens, H., Mulazimoglu, L., Trenholme, G., Klugman, K. P., Bonomo, R. A., et al. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-1-200401060-00008 · Cited by 631
Microbial Threats to Health: Emergence, Detection, and Response
Smolinski, M. S., Hamburg, M. A., & Lederberg, J. (2003) · Cited by 615
Efflux-mediated multiresistance in Gram-negative bacteria
Poole, K. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2004.00763.x · Cited by 613
Nosocomial Outbreak of Klebsiella Infection Resistant to Late-Generation Cephalosporins
Meyer, K. S., Urban, C., Eagan, J. A., Berger, B. J., & Rahal, J. J. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-119-5-199309010-00001 · Cited by 580
Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria
Li, J., Nation, R. L., Milne, R. W., Turnidge, J. D., & Coulthard, K. (2005) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2004.10.001 · Cited by 571
Paterson, D. L., Ko, W.-C., Von Gottberg, A., Mohapatra, S., Casellas, J. M., Goossens, H., Mulazimoglu, L., Trenholme, G., Klugman, K. P., Bonomo, R. A., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/420816 · Cited by 571
Micek, S. T., Lloyd, A. E., Ritchie, D. J., Reichley, R. M., Fraser, V. J., & Kollef, M. H. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.4.1306-1311.2005 · Cited by 526
Why is big Pharma getting out of antibacterial drug discovery?
Projan, S. J. (2003) · Current Opinion in Microbiology · doi:10.1016/j.mib.2003.08.003 · Cited by 503
Lack of development of new antimicrobial drugs: a potential serious threat to public health
Norrby, S. R., Nord, C. E., & Finch, R. (2005) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(05)01283-1 · Cited by 491
Wiener, J. (1999) · JAMA · doi:10.1001/jama.281.6.517 · Cited by 485
Bradford, P. A., Bratu, S., Urban, C., Visalli, M., Mariano, N., Landman, D., Rahal, J. J., Brooks, S., Cebular, S., & Quale, J. (2004) · Clinical Infectious Diseases · doi:10.1086/421495 · Cited by 485
Methicillin-Resistant Staphylococcus aureus: An Evolutionary, Epidemiologic, and Therapeutic Odyssey
Deresinski, S. (2005) · Clinical Infectious Diseases · doi:10.1086/427701 · Cited by 466
DiazGranados, C. A., Zimmer, S. M., Mitchel, K., & Jernigan, J. A. (2005) · Clinical Infectious Diseases · doi:10.1086/430909 · Cited by 459
SMITH, A. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2005.04.007 · Cited by 443
Woodford, N., Tierno, P. M., Young, K., Tysall, L., Palepou, M.-F. I., Ward, E., Painter, R. E., Suber, D. F., Shungu, D., Silver, L. L., et al. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.12.4793-4799.2004 · Cited by 442
Gales, A. C., Jones, R. N., Forward, K. R., Liñares, J., Sader, H. S., & Verhoef, J. (2001) · Clinical Infectious Diseases · doi:10.1086/320183 · Cited by 441
Eliopoulos, G. M., & Bush, K. (2001) · Clinical Infectious Diseases · doi:10.1086/319610 · Cited by 392
Fridkin, S. K., Hageman, J., McDougal, L. K., Mohammed, J., Jarvis, W. R., Perl, T. M., Tenover, F. C., & the Vancomycin‐Intermediate Staphylococcus aureus Epidemiology Study Group (2003) · Clinical Infectious Diseases · doi:10.1086/346207 · Cited by 344
Multidrug-Resistant Acinetobacter Extremity Infections in Soldiers
Davis, K. A., Moran, K. A., McAllister, C. K., & Gray, P. J. (2005) · Emerging Infectious Diseases · doi:10.3201/1108.050103 · Cited by 327
Gales, A. C., Jones, R. N., Turnidge, J., Rennie, R., & Ramphal, R. (2001) · Clinical Infectious Diseases · doi:10.1086/320186 · Cited by 309
Newer Systemic Antifungal Agents: Pharmacokinetics, Safety and Efficacy
Boucher, H. W., Groll, A. H., Chiou, C. C., & Walsh, T. J. (2004) · Drugs · doi:10.2165/00003495-200464180-00001 · Cited by 305
Landman, D., Quale, J. M., Mayorga, D., Adedeji, A., Vangala, K., Ravishankar, J., Flores, C., & Brooks, S. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.13.1515 · Cited by 301
Noskin, G. A., Rubin, R. J., Schentag, J. J., Kluytmans, J., Hedblom, E. C., Smulders, M., Lapetina, E., & Gemmen, E. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.15.1756 · Cited by 299
Obritsch, M. D., Fish, D. N., MacLaren, R., & Jung, R. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.12.4606-4610.2004 · Cited by 288
Methicillin-resistant–Staphylococcus aureus Hospitalizations, United States
Kuehnert, M. J., Hill, H. A., Kupronis, B. A., Tokars, J. I., Solomon, S. L., & Jernigan, D. B. (2005) · Emerging Infectious Diseases · doi:10.3201/eid1106.040831 · Cited by 287
Kang, C.-I., Kim, S.-H., Park, W. B., Lee, K.-D., Kim, H.-B., Kim, E.-C., Oh, M.-D., & Choe, K.-W. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.12.4574-4581.2004 · Cited by 267
Health and Economic Outcomes of Vancomycin-Resistant Enterococci
Carmeli, Y., Eliopoulos, G., Mozaffari, E., & Samore, M. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.19.2223 · Cited by 249
Antimicrobial Resistance Trends and Outbreak Frequency in United States Hospitals
Diekema, D. J., BootsMiller, B. J., Vaughn, T. E., Woolson, R. F., Yankey, J. W., Ernst, E. J., Flach, S. D., Ward, M. M., Franciscus, C. L. J., Pfaller, M. A., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/380457 · Cited by 249
The Antibiotic Pipeline — Challenges, Costs, and Values
Wenzel, R. P. (2004) · New England Journal of Medicine · doi:10.1056/nejmp048093 · Cited by 230
Antimicrobial drug development – the past, the present, and the future
Powers, J. H. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1465-0691.2004.1007.x · Cited by 224
Pulmonary infections in patients with cystic fibrosis
RAJAN, S. (2002) · Seminars in Respiratory Infections · doi:10.1053/srin.2002.31690 · Cited by 220
Recent trends in the epidemiology of invasive mycoses
Clark, T. A., & Hajjeh, R. A. (2002) · Current Opinion in Infectious Diseases · doi:10.1097/00001432-200212000-00003 · Cited by 210
Streit, J. M., Jones, R. N., Sader, H. S., & Fritsche, T. R. (2004) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2003.12.019 · Cited by 191
Bhavnani, S. M., Drake, J. A., Forrest, A., Deinhart, J. A., Jones, R. N., Biedenbach, D. J., & Ballow, C. H. (2000) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(99)00136-4 · Cited by 179
Talbot et al. (2006 42:657-68)
(2006) · Clinical Infectious Diseases · doi:10.1086/503200 · Cited by 166
Pseudomonas aeruginosa pneumonia
Garau, J., & Gomez, L. (2003) · Current Opinion in Infectious Diseases · doi:10.1097/00001432-200304000-00010 · Cited by 163
Schwaber, M. J., Navon-Venezia, S., Schwartz, D., & Carmeli, Y. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.5.2137-2139.2005 · Cited by 160
Invasive Aspergillus Rhinosinusitis in Patients with Acute Leukemia
Talbot, G. H., Huang, A., & Provencher, M. (1991) · Clinical Infectious Diseases · doi:10.1093/clinids/13.2.219 · Cited by 138
Self-citationMupirocin-Resistant, Methicillin-ResistantStaphylococcus aureus: Does Mupirocin Remain Effective?
Walker, E. S., Vasquez, J. E., Dula, R., et al. (2003) · Infection Control and Hospital Epidemiology · doi:10.1086/502218 · Cited by 137
Bradford, P. A., Weaver‐Sands, D. T., & Petersen, P. J. (2005) · Clinical Infectious Diseases · doi:10.1086/431673 · Cited by 133
Antibiotic Treatment of Multidrug-Resistant Organisms in Cystic Fibrosis
Conway, S. P., Brownlee, K. G., Denton, M., & Peckham, D. G. (2003) · American Journal of Respiratory Medicine · doi:10.1007/bf03256660 · Cited by 127
Taking inventory: antibacterial agents currently at or beyond Phase 1
Bush, K., Macielag, M. J., & Weidner‐Wells, M. A. (2004) · Current Opinion in Microbiology · doi:10.1016/j.mib.2004.08.013 · Cited by 126
Quale, J. M., Landman, D., Bradford, P. A., Visalli, M. A., Ravishankar, J., Flores, C., Mayorga, D., Vangala, K., & Adedeji, A. (2002) · Clinical Infectious Diseases · doi:10.1086/342577 · Cited by 96
Atypical Infections in Tsunami Survivors
Garzoni, C., Emonet, S., Legout, L., Benedict, R., Hoffmeyer, P. J., Bernard, L., & Garbino, J. (2005) · Emerging infectious diseases · doi:10.3201/eid1110.050715 · Cited by 93
Caspofungin: first approved agent in a new class of antifungals
Johnson, M. D., & Perfect, J. R. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.5.807 · Cited by 85
New advances in antibiotic development and discovery
Alekshun, M. N. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.2.117 · Cited by 51
Development of drugs for antimicrobial-resistant pathogens
Powers, J. H. (2003) · Current Opinion in Infectious Diseases · doi:10.1097/00001432-200312000-00006 · Cited by 41
Update on antifungal treatment of invasive Candida and Aspergillus infections
Maschmeyer, G., & Ruhnke, M. (2004) · Mycoses · doi:10.1111/j.1439-0507.2004.01003.x · Cited by 41
Invasive aspergillosis in patients with solid tumors
Ohmagari, N., Raad, I. I., Hachem, R. Y., & Kontoyiannis, D. P. (2004) · Cancer · doi:10.1002/cncr.20647 · Cited by 39
Aspergillosis in “Nonimmunocompromised” Critically Ill Patients
Denning, D. W. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2407004 · Cited by 37
Cephalosporins in clinical development
Page, M. G. P. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.8.973 · Cited by 37
Antiinfective biotechs face partnering gap
Sheridan, C. (2005) · Nature Biotechnology · doi:10.1038/nbt0205-155 · Cited by 7
Cited by
Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
Boucher, H. W., Talbot, G. H., Bradley, J. S., Edwards, J. E., Gilbert, D., Rice, L. B., Scheld, M., Spellberg, B., & Bartlett, J. (2009) · Clinical Infectious Diseases · doi:10.1086/595011 · Cited by 4,958
Self-citationAcinetobacter baumannii : Emergence of a Successful Pathogen
Peleg, A. Y., Seifert, H., & Paterson, D. L. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00058-07 · Cited by 3,316
Drugs for bad bugs: confronting the challenges of antibacterial discovery
Payne, D. J., Gwynn, M. N., Holmes, D. J., & Pompliano, D. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2201 · Cited by 2,512
Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern
Pitout, J. D., & Laupland, K. B. (2008) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(08)70041-0 · Cited by 2,044
David, M. Z., & Daum, R. S. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00081-09 · Cited by 1,972
Metadata
- Authors
- Talbot, G. H., Bradley, J., Edwards, J. E., Gilbert, D., Scheld, M., & Bartlett, J. G.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-03-01
- Volume
- 42
- Issue
- 5
- Pages
- 657-668
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2101273146
- Cited by
- 1,104
- References
- 69
- FWCI
- 90.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.